DOCSLIB.ORG

Jon Rees, Mark Abrahams, Victor Abu, Trevor Allan, Andrew Doble, Theresa Neale, Penny Nixon, Maxwell Saxty, Sarah Mee, Alison Co

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jon Rees, Mark Abrahams, Victor Abu, Trevor Allan, Andrew Doble, Theresa Neale, Penny Nixon, Maxwell Saxty, Sarah Mee, Alison Co Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. Sept 2014 Jon Rees,1 Mark Abrahams,2 Victor Abu,3 Trevor Allan,4 Andrew Doble,5 Theresa Neale,6 Penny Nixon,7 Maxwell Saxty,8 Sarah Mee,9 Alison Cooper,10 Kirsty Haves,11 and Jenny Lee12 1GP (Chair of Prostatitis Expert Reference Group), Backwell and Nailsea Medical Group, Bristol; 2Pain Consultant, Addenbrooke’s Hospital, Cambridge; 3Clinical Nurse Specialist – Prostate, University College London Hospitals, London; 4Patient Representative; 5Consultant Urologist, Addenbrooke’s Hospital, Cambridge; 6Urology Clinical Nurse Specialist, South Warwickshire Foundation Trust; 7Physiotherapist Specialist, Addenbrooke’s Hospital, Cambridge; 8Cognitive Behavioural Therapist, Addenbrooke’s Hospital, Cambridge; 9Policy and Evidence Manager, Prostate Cancer UK; 10Senior Research Analyst, Prostate Cancer UK; 11Senior Account Manager, Hayward Medical Communications; 12Project Manager, Hayward Medical Communications A quick reference guide version of this guideline can be downloaded from: www.prostatecanceruk.org/prostatitisguideline ENDORSED BY September 2014 1 (due for review September 2017) Page Prostate Cancer UK is a registered charity in England and Wales (1005541) and in Scotland (SC039332). A company limited by guarantee registered number 2653887 (England and Wales). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. Sept 2014 Introduction ..................................................................................................................................................................... 4 Overview ........................................................................................................................................................................ 4 Guideline objectives ...................................................................................................................................................... 5 Guideline population ...................................................................................................................................................... 6 Methods ............................................................................................................................................................................ 7 Prostatitis Expert Reference Group ............................................................................................................................... 7 Literature search ............................................................................................................................................................ 7 Search protocol .......................................................................................................................................................... 7 Level of evidence ....................................................................................................................................................... 8 Delphi panel ................................................................................................................................................................... 8 Process ...................................................................................................................................................................... 8 Results ....................................................................................................................................................................... 9 Priorities for implementation ....................................................................................................................................... 10 Management recommendations – initial presentation .............................................................................................. 11 Introduction .................................................................................................................................................................. 11 Signs and symptoms ................................................................................................................................................... 11 Clinical assessment and diagnosis ............................................................................................................................. 16 Patient history .......................................................................................................................................................... 16 Patient communications ........................................................................................................................................... 18 Physical examinations ............................................................................................................................................. 18 Investigations ........................................................................................................................................................... 19 Diagnosis ................................................................................................................................................................. 23 Referral to a specialist setting .................................................................................................................................. 23 Treatment strategies .................................................................................................................................................... 23 Alpha-blockers ......................................................................................................................................................... 23 Antibiotics ................................................................................................................................................................. 25 Pain relief ................................................................................................................................................................. 29 5-alpha-reductase inhibitors .................................................................................................................................... 30 Combination/multimodal therapy ............................................................................................................................. 31 Management recommendations – follow-up .............................................................................................................. 33 Referral for specialist assessment and management ................................................................................................. 33 2 Treatment strategies .................................................................................................................................................... 33 Pain relief ................................................................................................................................................................. 33 Page Prostate Cancer UK is a registered charity in England and Wales (1005541) and in Scotland (SC039332). A company limited by guarantee registered number 2653887 (England and Wales). Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. Sept 2014 Specialist physiotherapy .......................................................................................................................................... 36 Phytotherapy ............................................................................................................................................................ 38 Cognitive behavioural therapy and psychotherapy .................................................................................................. 38 Surgical intervention ................................................................................................................................................ 39 Research recommendations ........................................................................................................................................ 40 Acknowledgements ...................................................................................................................................................... 41 Updating the guideline ................................................................................................................................................. 41 Conflicts of interest ...................................................................................................................................................... 41 Comments or feedback ................................................................................................................................................ 41 References ..................................................................................................................................................................... 42 Appendix A – Relevant supporting information ........................................................................................................ 48 Appendix B – Prostatitis Expert Reference Group Members ................................................................................... 49 Supplementary Appendix 1 – Literature review protocol ........................................................................................
Load more

Recommended publications
  • The Male Reproductive System
    Management of Men’s Reproductive 3 Health Problems Men’s Reproductive Health Curriculum Management of Men’s Reproductive 3 Health Problems © 2003 EngenderHealth. All rights reserved. 440 Ninth Avenue New York, NY 10001 U.S.A. Telephone: 212-561-8000 Fax: 212-561-8067 e-mail: [email protected] www.engenderhealth.org This publication was made possible, in part, through support provided by the Office of Population, U.S. Agency for International Development (USAID), under the terms of cooperative agreement HRN-A-00-98-00042-00. The opinions expressed herein are those of the publisher and do not necessarily reflect the views of USAID. Cover design: Virginia Taddoni ISBN 1-885063-45-8 Printed in the United States of America. Printed on recycled paper. Library of Congress Cataloging-in-Publication Data Men’s reproductive health curriculum : management of men’s reproductive health problems. p. ; cm. Companion v. to: Introduction to men’s reproductive health services, and: Counseling and communicating with men. Includes bibliographical references. ISBN 1-885063-45-8 1. Andrology. 2. Human reproduction. 3. Generative organs, Male--Diseases--Treatment. I. EngenderHealth (Firm) II. Counseling and communicating with men. III. Title: Introduction to men’s reproductive health services. [DNLM: 1. Genital Diseases, Male. 2. Physical Examination--methods. 3. Reproductive Health Services. WJ 700 M5483 2003] QP253.M465 2003 616.6’5--dc22 2003063056 Contents Acknowledgments v Introduction vii 1 Disorders of the Male Reproductive System 1.1 The Male
    [Show full text]
  • Let's Talk About What's Hard
    Let’s Talk About What’s Hard “Bobby” Duc Tran, MD, MSc Assistant Professor, Emory University 2017 HoG State Meeting Case Presentation March 3, 2017 WARNING The following presentation contains some foul language, nudity, and images that some viewers may find upsetting Case Presentation • 32yo white male • Past medical history: • severe hemophilia B • hemophilic arthropathy of bilateral knees and elbows • Marfan’s syndrome • atrial fibrillation • blind in one eye • hepatitis C • Current hemophilia treatment: Aprolix • Previous issues with mixing the factor. Case Presentation • Past surgeries: • Aortic root repair • Full dentition extraction • Bilateral knee arthroscopic synevectomies at 5 and 7 yo • Left orchiectomy for testicular torsion • Last seen in clinic for his annual comprehensive visit in 9/2016 Case Presentation • Called to the HTC clinic nurse on 12/5/2016 • Embarrassingly he reported: • This morning “my penis and testicles are blackish purple and feels like a bleed” • I had sex with my wife last night • Last infused 3 days ago and is not due for next infusion until tomorrow • “This has never happened before” How to talk about this? • Approach from a professional standpoint • Discuss these topics when discussing safe sexual practices • Gauge the patient’s comfort with using medical terms • Nicknames used: • Dick, dong, schlong, wiener, peen, so many more • Not wenis What to do first? • When was the bleeding recognized? • Did you hear/feel a “pop”? • Recognize associated injuries • Urethra, bladder, vascular • Consider GU referral
    [Show full text]
  • Chronic Bacterial Prostatitis Treated with Phage Therapy After Multiple Failed Antibiotic Treatments
    CASE REPORT published: 10 June 2021 doi: 10.3389/fphar.2021.692614 Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments Apurva Virmani Johri 1*, Pranav Johri 1, Naomi Hoyle 2, Levan Pipia 2, Lia Nadareishvili 2 and Dea Nizharadze 2 1Vitalis Phage Therapy, New Delhi, India, 2Eliava Phage Therapy Center, Tbilisi, Georgia Background: Chronic Bacterial Prostatitis (CBP) is an inflammatory condition caused by a persistent bacterial infection of the prostate gland and its surrounding areas in the male pelvic region. It is most common in men under 50 years of age. It is a long-lasting and Edited by: ’ Mayank Gangwar, debilitating condition that severely deteriorates the patient s quality of life. Anatomical Banaras Hindu University, India limitations and antimicrobial resistance limit the effectiveness of antibiotic treatment of Reviewed by: CBP. Bacteriophage therapy is proposed as a promising alternative treatment of CBP and Gianpaolo Perletti, related infections. Bacteriophage therapy is the use of lytic bacterial viruses to treat University of Insubria, Italy Sandeep Kaur, bacterial infections. Many cases of CBP are complicated by infections caused by both Mehr Chand Mahajan DAV College for nosocomial and community acquired multidrug resistant bacteria. Frequently encountered Women Chandigarh, India Tamta Tkhilaishvili, strains include Vancomycin resistant Enterococci, Extended Spectrum Beta Lactam German Heart Center Berlin, Germany resistant Escherichia coli, other gram-positive organisms such as Staphylococcus and Pooria Gill, Streptococcus, Enterobacteriaceae such as Klebsiella and Proteus, and Pseudomonas Mazandaran University of Medical Sciences, Iran aeruginosa, among others. *Correspondence: Case Presentation: We present a patient with the typical manifestations of CBP.
    [Show full text]
  • Diagnosis and Management of Infertility Due to Ejaculatory Duct Obstruction: Summary Evidence ______
    Vol. 47 (4): 868-881, July - August, 2021 doi: 10.1590/S1677-5538.IBJU.2020.0536 EXPERT OPINION Diagnosis and management of infertility due to ejaculatory duct obstruction: summary evidence _______________________________________________ Arnold Peter Paul Achermann 1, 2, 3, Sandro C. Esteves 1, 2 1 Departmento de Cirurgia (Disciplina de Urologia), Universidade Estadual de Campinas - UNICAMP, Campinas, SP, Brasil; 2 ANDROFERT, Clínica de Andrologia e Reprodução Humana, Centro de Referência para Reprodução Masculina, Campinas, SP, Brasil; 3 Urocore - Centro de Urologia e Fisioterapia Pélvica, Londrina, PR, Brasil INTRODUCTION tion or perineal pain exacerbated by ejaculation and hematospermia (3). These observations highlight the Infertility, defined as the failure to conceive variability in clinical presentations, thus making a after one year of unprotected regular sexual inter- comprehensive workup paramount. course, affects approximately 15% of couples worl- EDO is of particular interest for reproduc- dwide (1). In about 50% of these couples, the male tive urologists as it is a potentially correctable factor, alone or combined with a female factor, is cause of male infertility. Spermatogenesis is well- contributory to the problem (2). Among the several -preserved in men with EDO owing to its obstruc- male infertility conditions, ejaculatory duct obstruc- tive nature, thus making it appealing to relieve the tion (EDO) stands as an uncommon causative factor. obstruction and allow these men the opportunity However, the correct diagnosis and treatment may to impregnate their partners naturally. This review help the affected men to impregnate their partners aims to update practicing urologists on the current naturally due to its treatable nature. methods for diagnosis and management of EDO.
    [Show full text]
  • Hemospermia: Long-Term Outcome in 165 Patients
    International Journal of Impotence Research (2013) 26, 83–86 & 2013 Macmillan Publishers Limited All rights reserved 0955-9930/13 www.nature.com/ijir ORIGINAL ARTICLE Hemospermia: long-term outcome in 165 patients J Zargooshi, S Nourizad, S Vaziri, MR Nikbakht, A Almasi, K Ghadiri, S Bidhendi, H Khazaie, H Motaee, S Malek-Khosravi, N Farshchian, M Rezaei, Z Rahimi, R Khalili, L Yazdaani, K Najafinia and M Hatam Long-term course of hemospermia has not been addressed in the sexual medicine literature. We report our 15 years’ experience. From 1997 to 2012, 165 patients presented with hemospermia. Mean age was 38 years. Mean follow-up was 83 months. Laboratory evaluation and testis and transabdominal ultrasonography was done in all. Since 2008, all sonographies were done by the first author. One patient had urinary tuberculosis, one had bladder tumor and three had benign lesions at verumontanum. One patient had bilateral partial ejaculatory duct obstruction by stones. All six patients had persistent, frequently recurring or high-volume hemospermia. All pathologies were found in young patients. In the remaining 159 patients (96%), empiric treatment was given with a fluoroquinolone (Ciprofloxacin) plus an nonsteroidal anti-inflammatory drug (Celecoxib). In our 15 years of follow-up, no patient later developed life-threatening disease. Diagnostic evaluation of hemospermia is not worthwhile in the absolute majority of cases. Advanced age makes no difference. Only high-risk patients need to be evaluated. The vast majority of cases may be safely and
    [Show full text]
  • Chronic Prostatitis: a Possible Cause of Hematospermia
    pISSN: 2287-4208 / eISSN: 2287-4690 World J Mens Health 2015 August 33(2): 103-108 http://dx.doi.org/10.5534/wjmh.2015.33.2.103 Original Article Chronic Prostatitis: A Possible Cause of Hematospermia Gilho Lee Department of Urology, Dankook University Medical College, Cheonan, Korea Purpose: While hematospermia is mainly caused by genitourinary inflammatory disorders, very few studies have been published on prostatitis-associated hematospermia (PAH) diagnosed using robust prostatitis evaluation methods. Therefore, we have evaluated the incidence of PAH by using systematic methods for evaluating prostatitis. Materials and Methods: We evaluated 37 hematospermia patients from a single hospital over the last five years. We classified the patients into PAH versus hematospermia without any evidence of prostatitis (HWP) by using a NIH-Chronic Prostatitis Symptom Index questionnaire and expressed prostatic secretion studies. Results: The mean age was 55.89±14.87 years, and the patients were grouped into two groups: one group had 12 HWP patients and the other 25 PAH patients. PAH patients were further sub-classified: chronic bacterial prostatitis (3 patients), chronic nonbacterial prostatitis (10 patients), prostadynia (7 patients), and asymptomatic prostatitis (5 patients). We found Enterococcus faecalis in the three chronic bacterial prostatitis patients. We could not find any statistically significant difference between the PAH and the HWP groups in terms of the age interval, serum prostate-specific antigen level, and prostate volume. Even though there was no statistically significant difference in the items about urination between the two groups, we found a statistically significant difference in the quality of life (QoL) impact for the patients in this study.
    [Show full text]
  • Microhematuria and Urinary Tract Infections
    1/30/2018 MICROHEMATURIA AND URINARY TRACT INFECTIONS ANEESA HUSAIN, PA-C USMD CANCER CENTER ARLINGTON - UROLOGY I HAVE NO FINANCIAL DISCLOSURES THAT WOULD BE A POTENTIAL CONFLICT OF INTEREST WITH THIS PRESENTATION. MICROHEMATURIA TOPICS OF DISCUSSION • DEFINITION • HISTORY • PHYSICAL EXAM • DIFFERENTIAL DIAGNOSES • WORK UP • TREATMENT • WHEN TO REFER? 1 1/30/2018 MICROHEMATURIA DEFINED AS.. • ≥3 RBCs per HPF (HIGH POWER FIELD) ON URINE MICROSCOPY • SHOULD NOT BASE SOLELY ON ONE DIPSTICK READING • CAN CORRELATE TO DIPSTICK URINE ANALYSIS • TRACE, SMALL, MODERATE, LARGE https://www.auanet.org/guidelines/asymptomatic-microhematuria-(2012-reviewed-and-validity-confirmed-2016) MICROHEMATURIA TOP DIFFERENTIAL DIAGNOSES • UTI/PROSTATITIS • KIDNEY STONES • URINARY TRACT OBSTRUCTION • URINARY TRACT MALIGNANCY • NEPHROLOGIC SOURCES MICROHEMATURIA HISTORY • NEW DIAGNOSIS OF MICROHEMATURIA? • PRIOR HISTORY OF GROSS OR MICROHEMATURIA? • PRIOR WORK UP • COMORBIDITIES • PELVIC RADIATION • SURGICAL HISTORY • FOR WOMEN, ASK ABOUT MENSES AND/OR MENOPAUSE • ANTICOAGULATION OR BLOOD THINNERS • SYMPTOMS 2 1/30/2018 MICROHEMATURIA HISTORY - SYMPTOMS • DYSURIA • FREQUENCY • URGENCY • DIFFICULTY VOIDING • INCONTINENCE – PAD USAGE • ABDOMINAL OR BACK PAIN • PERINEAL PAIN MICROHEMATURIA PHYSICAL EXAM • ABDOMINAL EXAM • CVA/FLANK TENDERNESS • GU EXAM • MALE – CONSIDER MEATAL STENOSIS, BALANITIS, TESTICULAR PAIN, PROSTATITIS, PROSTATE ENLARGEMENT • FEMALE – CONSIDER VAGINAL BLEEDING, YEAST INFECTION, ATROPHIC VAGINITIS MICROHEMATURIA DIFFERENTIAL DIAGNOSES • UTI/PROSTATITIS
    [Show full text]
  • Hematospermia: Footprint of Severe Uncontrolled Hypertension
    Hematology & Transfusion International Journal Mini Review Open Access Hematospermia: footprint of severe uncontrolled hypertension Keywords: hematospermia, oligozoospermia, azoospermia, Volume 3 Issue 2 - 2016 asthenozoospermia, hematuria Ali Shalizar Jalali Introduction Department of Basic Sciences, Urmia University, Iran Hematospermia, also known as hemospermia, bloody sperm and Correspondence: Ali Shalizar Jalali, Histology and Embryology sanguineous sperm, is a commonly isolated symptom characterized Research Laboratories, Department of Basic Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran, Fax by the presence of glossy visible blood in semen and represents 1% 00984432771926, Tel 00984431942593, 1 of all andrological and urological symptoms. Historical evidences Email [email protected], [email protected] revealed that it had been reported by Hippocrates, Pares, Morgagni, Velpeau, Fournier and Guyon.2,3 It is usually painless but can be seen Received: October 26, 2016 | Published: December 22, 2016 along with hematuria, frequency, dysuria and scrotal pain as well as infertility.4,5 It has been indicated that hematospermia can result in azoospermia, oligozoospermia and asthenozoospermia leading 4. Weidner W, Jantos C, Schumacher F, et al. Recurrent haemospermia. to male infertility.6,7 Moreover, it often leads to substantial adverse Underlying urogenital anomalies and efficacy of imaging procedures.Br psychological consequences in the patient.8 It was found that 77.50% J Urol. 1991;67(3):317–323. of men with hematospermia had experienced only one or two episodes 5. Jones DJ. Haemospermia: a prospective study. British Journal of prior to visiting urologists.5 The incidence of hematospermia has been Urology. 1991;67(1):88–90. reported as one in every 5,000 new patients presenting to urological 6.
    [Show full text]
  • Prostatitis T I N Daniel A
    C Diagnosis and Management of O N Acute and Chronic Prostatitis T I N Daniel A. Shoskes Floyd Katske U Sun Kim I N G rostatitis syndromes pre- Prostatitis syndromes are some of the most poorly understood yet sent an interesting con- prevalent problems in urology. There is little controversy over acute trast in incidence and prostatitis, a urinary tract infection with systemic symptoms and E understanding. Acute and signs that typically responds to antimicrobial therapy. By contrast, D Pchronic bacterial prostatitis are the chronic prostatitis syndromes have so far eluded attempts to relatively uncommon, but well- U understand their pathophysiology and design effective therapies, C understood urinary tract infec- resulting in great frustration among patients and health care tions caused by established providers. An accurate diagnosis and a multidisciplinary approach A uropathogens. They are typically T responsive to appropriate antimi- are essential to assist men with this often debilitating condition. crobial therapy. By contrast, the I much more common nonbacteri- O Objectives al prostatitis and prostatodynia N syndromes remain an enigma, This educational activity is designed for nurses and other health both in etiology, appropriate care professionals who care for and educate patients regarding acute workup, and therapy. The rough- and chronic prostatitis. The multiple choice examination that follows ly 2 million annual outpatient is designed to test your achievement of the following educational objec- visits for chronic prostatitis in tives. After studying this offering, you will be able to: the United States (Collins, 1. Define acute and chronic prostatitis. Stafford, O’Leary, & Barry, 1998) 2. Discuss the diagnosis of acute and chronic prostatitis.
    [Show full text]
  • Semen Analysis
    3 Semen Analysis Meaghanne K. Caraballo, Alyssa M. Giroski, Rakesh Sharma, and Ashok Agarwal Introduction Semen Collection Conceiving a child is often one of the most desired goals in a Semen samples should ideally be collected after abstaining from couple’s relationship, but unfortunately this cannot be achieved ejaculation for a minimum of 2 days but not more than 1 week [3]. naturally in all cases. Infertility is a couple problem that affects Longer abstinence times can result in hyperspermia or a semen 15%–20% of the population. Of these, 30%–40% can be attrib- volume greater than 5 mL. When the patient is instructed to uted to male-factor infertility, and 30%–40% can be attributed to provide a semen sample, they should be given the appropriate female-factor infertility. In the remaining 20%, there is a com- instructions to ensure that the semen sample is collected prop- bination of both male and female factors [1,2]. To assess male erly and free of contaminants that may affect semen quality [4]. factor infertility, semen analysis is the primary test that a physi- It is recommended that semen samples be collected via masturba- cian will order. A formal laboratory evaluation of semen analysis tion only into a sterile, wide-mouthed plastic container. Samples requires adherence to strict guidelines according to the World collected via coitus interruptus should not be accepted because Health Organization (WHO) guidelines [3]. they will be contaminated with cellular debris and bacteria. One Evaluation of semen is performed using standardized refer- of the major concerns with this method of collection is that the ence ranges (Table 3.1) established by WHO in 2010 [3].
    [Show full text]
  • Prostatitis Diagnosis and Treatment Gretchen Dickson
    CLINICAL Prostatitis Diagnosis and treatment Gretchen Dickson gland following intraprostatic reflux of urine Prostatitis is a spectrum of disorders that impacts a significant number of men. infected with organisms such as Escherichia coli, Acute bacterial prostatitis may be a life-threatening event requiring prompt Enterococcus and Proteus species.5,6 Men with recognition and treatment with antibiotic therapy. Chronic bacterial prostatitis has chronic indwelling catheters, diabetes mellitus, a more indolent course and also requires antibiotic therapy for resolution. Chronic immunosuppression, or who intermittently prostatitis/chronic pelvic pain syndrome is the most common manifestation of prostatitis and may be the most difficult to treat. Asymptomatic inflammatory perform self-catheterisation, are at higher risk prostatitis is an incidental finding of unclear significance. Understanding the of developing ABP due to their increased risk of diagnostic and management strategies for each of these entities is critical for bacterial colonisation of the urethra.6,7 There is general practitioners in caring for their male patients. no evidence that perineal trauma from bicycle or horseback riding, dehydration or sexual abstinence Keywords are risk factors for ABP. prostatitis; bacterial infections; pelvic pain The clinical presentation of ABP may be highly variable with symptoms ranging from mild to severe.6 Classic symptoms include: Up to 8% of Australian men report having • fever urogenital pain at any given time, with • chills 15% of men
    [Show full text]
  • Haematospermia
    CLINICAL Haematospermia Nandu Dantanarayana Background aematospermia refers to of assessment is to avoid missing the presence of blood in the malignancy, particularly prostate cancer. Haematospermia is an alarming H ejaculate. The epidemiology of Testicular, bladder and urethral cancer symptom for patients. Reassuringly, haematospermia is poorly described very rarely cause haematospermia, and most cases are benign in origin and because the majority of men do not only if advanced.2 self-limiting. Occasionally, however, an witness their semen.1 For men who underlying malignancy is responsible experience haematospermia, it can Approach and must not be missed by the treating provoke significant anxiety. While most A focused history and examination doctor. cases of haematospermia are benign, it is the initial step in the evaluation of Objective may be secondary to a sinister underlying haematospermia. It is important to pathology and require systematic differentiate between haematospermia The aim of this article is to review the evaluation by the general practitioner and pseudo-haematospermia. The latter causes, diagnosis and management (GP).2 A number of patients may require is haematuria or blood originating from of haematospermia in the primary further evaluation by a urologist or other the patient’s partner. If both haematuria care setting. This review will describe specialist, although even among high-risk and haematospermia are present, an approach to haematospermia that populations, malignancy is rare.3 the approach should be as per the general practitioners (GPs) can apply to haematuria pathway (including urine daily practice. Anatomy cytology, computed tomography [CT] Several anatomical structures contribute intravenous pyelogram and cystoscopy).7 Discussion to the ejaculate and any one of these may Assess for the presence of the red There are numerous potential causes be the source of the haematospermia.
    [Show full text]